James W. Schurr
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
James W. Schurr has a total of 73 co-authors. Here are the top co-authors by number of shared publications:
- Joyce Wald
Cardiovascular Medicine Division, Perelman School of Medicine, Hospital of the University of Pennsylvania, Philadelphia, Philadelphia
3 shared publications Marisa Cevasco
Cardiovascular Surgery Division, Perelman School of Medicine, Hospital of the University of Pennsylvania, Philadelphia, Philadelphia
3 shared publicationsAditya Parikh
Cardiovascular Medicine Division, Perelman School of Medicine, Hospital of the University of Pennsylvania, Philadelphia, Philadelphia
2 shared publicationsAllison J McLarty
Stony Brook University Hospital Department of Surgery, Stony Brook, NY, USA
2 shared publicationsAlyson Brown
Cardiovascular Medicine Division, Perelman School of Medicine, Hospital of the University of Pennsylvania, Philadelphia, Philadelphia
2 shared publicationsChristian Bermudez
Hospital of the University of Pennsylvania Perelman School of Medicine Philadelphia Pennsylvania USA
2 shared publications
Latest Publications
- 15 October 2026
- Published by Wolters Kluwer Health in ASAIO Journal
Microcirculatory Hemodynamic Changes on Full Support Microaxial Flow Pump in Cardiogenic Shock
Impaired microcirculation predicts mortality in cardiogenic shock independent of systemic hemodynamics, yet current treatment strategies focus primarily on restoring macrocirculatory markers. We studied whether full-support microaxial flow pump (mAFP) therapy improves sublingual microcirculation in cardiogenic shock. A prospective, single-arm, observational study of serial sublingual microcirculation imaging via incident darkfield handheld videomicroscopy was performed in 18 cardiogenic shock patients undergoing Impella 5.5 (mAFP) placement. Microvascular flow index (MFI), microvascular heterogeneity index (MHI), proportion of perfused vessels (PPV), and perfused vessel density (PVD) were measured. Eighteen patients were enrolled. Microvascular flow index ( p = 0.004), MHI ( p = 0.055), PPV ( p = 0.003), and PVD ( p = 0.067) improved immediately on support, including when adjusted for vasoactive-inotropic score. Improvement in MFI, MHI, PPV, or PVD was most pronounced in those with impaired baseline microcirculatory hemodynamics (all p < 0.05), whereas those with preserved baseline values demonstrated no change. Improved agreement between systemic and microcirculatory hemodynamics was observed in association with mAFP support, and none experienced worsening microcirculatory function. These exploratory findings suggest full-support mAFPs may improve impaired microcirculation during cardiogenic shock, although device-specific effects cannot be isolated from overall clinical improvement; validation in larger studies is warranted. Although agreement between systemic and microcirculatory hemodynamic markers improved, no macrohemodynamic marker proved sufficient to ensure adequate microcirculatory perfusion.
- 15 October 2026
- Published by Wolters Kluwer Health in ASAIO Journal
Microcirculatory Hemodynamic Changes on Full Support Microaxial Flow Pump in Cardiogenic Shock
Impaired microcirculation predicts mortality in cardiogenic shock independent of systemic hemodynamics, yet current treatment strategies focus primarily on restoring macrocirculatory markers. We studied whether full-support microaxial flow pump (mAFP) therapy improves sublingual microcirculation in cardiogenic shock. A prospective, single-arm, observational study of serial sublingual microcirculation imaging via incident darkfield handheld videomicroscopy was performed in 18 cardiogenic shock patients undergoing Impella 5.5 (mAFP) placement. Microvascular flow index (MFI), microvascular heterogeneity index (MHI), proportion of perfused vessels (PPV), and perfused vessel density (PVD) were measured. Eighteen patients were enrolled. Microvascular flow index ( p = 0.004), MHI ( p = 0.055), PPV ( p = 0.003), and PVD ( p = 0.067) improved immediately on support, including when adjusted for vasoactive-inotropic score. Improvement in MFI, MHI, PPV, or PVD was most pronounced in those with impaired baseline microcirculatory hemodynamics (all p < 0.05), whereas those with preserved baseline values demonstrated no change. Improved agreement between systemic and microcirculatory hemodynamics was observed in association with mAFP support, and none experienced worsening microcirculatory function. These exploratory findings suggest full-support mAFPs may improve impaired microcirculation during cardiogenic shock, although device-specific effects cannot be isolated from overall clinical improvement; validation in larger studies is warranted. Although agreement between systemic and microcirculatory hemodynamic markers improved, no macrohemodynamic marker proved sufficient to ensure adequate microcirculatory perfusion.
- 1 September 2026
- Published by Wolters Kluwer Health in Circulation: Heart Failure
- Vol. 19 (9)
Cardiogenic Shock Systems of Referral: Right Patient, Right Place, Right Time
- 1 September 2026
- Published by Wolters Kluwer Health in Circulation: Heart Failure
- Vol. 19 (9)
Cardiogenic Shock Systems of Referral: Right Patient, Right Place, Right Time
- Open Access
- 26 August 2026
- Published by Elsevier in JACC: Advances
- Vol. 5 (8)
Bayesian Meta-Analysis of Transcatheter Mitral Valve Edge-to-Edge Repair for Secondary Mitral Regurgitation in Heart Failure
- 26 August 2026
- Published by Elsevier in JACC: Advances
- Vol. 5 (8)
Open AccessBayesian Meta-Analysis of Transcatheter Mitral Valve Edge-to-Edge Repair for Secondary Mitral Regurgitation in Heart Failure
- Open Access
- 15 August 2026
- Published by Elsevier in JACC: Advances
- Vol. 5 (9)
Advancing Microcirculation Research in Advanced Heart Failure
- 15 August 2026
- Published by Elsevier in JACC: Advances
- Vol. 5 (9)
Open AccessAdvancing Microcirculation Research in Advanced Heart Failure
- 14 October 2024
- Published by Wolters Kluwer Health in ASAIO Journal
- Vol. 71 (4) , 300-307
Hemodynamic Support With the Impella 5.5 Acute Mechanical Circulatory Support Device
The Impella 5.5 is increasingly used as a bridge to recovery or heart replacement therapies despite lack of clinical trial evidence. We report real-world outcomes and hemodynamic effects of 150 consecutive patients from a single, high-volume center. Primary outcome was incidence of recovery, durable left ventricular assist device (LVAD), or heart transplant compared with incidence of death at 90 days. Secondary outcomes included hemodynamic trends and upgrade to veno-arterial extracorporeal membrane oxygenation (VA-ECMO) support. The composite endpoint occurred in 59.3% and death in 18.8% of patients (incidence rate ratio: 8.1 [95% confidence interval {CI}: 5.4–12.2], p < 0.001). Decreases in pulmonary artery diastolic pressure (PADP) (p = 0.026), estimated pulmonary effective arterial elastance (Ea) (p < 0.001), and vasoactive-inotropic score (VIS) (p < 0.001) occurred during Impella 5.5 support. Pulmonary artery diastolic pressure correlated with estimated Ea (p < 0.001), suggesting improved right ventricle (RV) afterload with left ventricle (LV) unloading. Veno-arterial extracorporeal membrane oxygenation upgrade occurred in 11.3% of patients who had higher baseline right atrial pressure (RAP) (16.0 [9.0–20.5] vs. 9.0 [7.0–12.0], p = 0.022), PADP (28.5 [25.0–31.0] vs. 23.0 [18.0–28.0], p = 0.011), and lower pulmonary artery pulsatility index (PAPi) (1.45 [0.82–3.45] vs. 2.5 [1.65–3.86], p = 0.029). Upgrade patients had higher repeated measures trends in RAP (p < 0.001) and PADP (p = 0.015). The Impella 5.5 improved hemodynamics and effectively bridged to recovery or heart replacement therapies. Co-existing RV dysfunction can be supported on Impella 5.5 with careful hemodynamic trend monitoring.
- 14 October 2024
- Published by Wolters Kluwer Health in ASAIO Journal
- Vol. 71 (4) , 300-307
Hemodynamic Support With the Impella 5.5 Acute Mechanical Circulatory Support Device
The Impella 5.5 is increasingly used as a bridge to recovery or heart replacement therapies despite lack of clinical trial evidence. We report real-world outcomes and hemodynamic effects of 150 consecutive patients from a single, high-volume center. Primary outcome was incidence of recovery, durable left ventricular assist device (LVAD), or heart transplant compared with incidence of death at 90 days. Secondary outcomes included hemodynamic trends and upgrade to veno-arterial extracorporeal membrane oxygenation (VA-ECMO) support. The composite endpoint occurred in 59.3% and death in 18.8% of patients (incidence rate ratio: 8.1 [95% confidence interval {CI}: 5.4–12.2], p < 0.001). Decreases in pulmonary artery diastolic pressure (PADP) (p = 0.026), estimated pulmonary effective arterial elastance (Ea) (p < 0.001), and vasoactive-inotropic score (VIS) (p < 0.001) occurred during Impella 5.5 support. Pulmonary artery diastolic pressure correlated with estimated Ea (p < 0.001), suggesting improved right ventricle (RV) afterload with left ventricle (LV) unloading. Veno-arterial extracorporeal membrane oxygenation upgrade occurred in 11.3% of patients who had higher baseline right atrial pressure (RAP) (16.0 [9.0–20.5] vs. 9.0 [7.0–12.0], p = 0.022), PADP (28.5 [25.0–31.0] vs. 23.0 [18.0–28.0], p = 0.011), and lower pulmonary artery pulsatility index (PAPi) (1.45 [0.82–3.45] vs. 2.5 [1.65–3.86], p = 0.029). Upgrade patients had higher repeated measures trends in RAP (p < 0.001) and PADP (p = 0.015). The Impella 5.5 improved hemodynamics and effectively bridged to recovery or heart replacement therapies. Co-existing RV dysfunction can be supported on Impella 5.5 with careful hemodynamic trend monitoring.
- Open Access
- 8 March 2024
- Published by Wiley in Artificial Organs
- Vol. 48 (8) , 921-931
Multicenter evaluation of left ventricular assist device implantation with or without ECMO bridge in cardiogenic shock
Background: The efficacy of extracorporeal membrane oxygenation (ECMO) as a bridge to left ventricular assist device (LVAD) remains unclear, and recipients of the more contemporary HeartMate 3 (HM3) LVAD are not well represented in previous studies. We therefore undertook a multicenter, retrospective study of this population.Methods and Results: INTERMACS 1 LVAD recipients from five U.S. centers were included. In‐hospital and one‐year outcomes were recorded. The primary outcome was the overall mortality hazard comparing ECMO versus non‐ECMO patients by propensity‐weighted survival analysis. Secondary outcomes included survival by LVAD type, as well as postoperative and one‐year outcomes. One hundred and twenty‐seven patients were included; 24 received ECMO as a bridge to LVAD. Mortality was higher in patients bridged with ECMO in the primary analysis (HR 3.22 [95%CI 1.06–9.77], p = 0.039). Right ventricular assist device was more common in the ECMO group (ECMO: 54.2% vs non‐ECMO: 11.7%, p < 0.001). Ischemic stroke was higher at one year in the ECMO group (ECMO: 25.0% vs non‐ECMO: 4.9%, p = 0.006). Among the study cohort, one‐year mortality was lower in HM3 than in HeartMate II (HMII) or HeartWare HVAD (10.5% vs 46.9% vs 31.6%, respectively; p < 0.001) recipients. Pump thrombosis at one year was lower in HM3 than in HMII or HVAD (1.8% vs 16.1% vs 16.2%, respectively; p = 0.026) recipients.Conclusions: Higher mortality was observed with ECMO as a bridge to LVAD, likely due to higher acuity illness, yet acceptable one‐year survival was seen compared with historical rates. The receipt of the HM3 was associated with improved survival compared with older generation devices.
- 8 March 2024
- Published by Wiley in Artificial Organs
- Vol. 48 (8) , 921-931
Open AccessMulticenter evaluation of left ventricular assist device implantation with or without ECMO bridge in cardiogenic shock
Background: The efficacy of extracorporeal membrane oxygenation (ECMO) as a bridge to left ventricular assist device (LVAD) remains unclear, and recipients of the more contemporary HeartMate 3 (HM3) LVAD are not well represented in previous studies. We therefore undertook a multicenter, retrospective study of this population.Methods and Results: INTERMACS 1 LVAD recipients from five U.S. centers were included. In‐hospital and one‐year outcomes were recorded. The primary outcome was the overall mortality hazard comparing ECMO versus non‐ECMO patients by propensity‐weighted survival analysis. Secondary outcomes included survival by LVAD type, as well as postoperative and one‐year outcomes. One hundred and twenty‐seven patients were included; 24 received ECMO as a bridge to LVAD. Mortality was higher in patients bridged with ECMO in the primary analysis (HR 3.22 [95%CI 1.06–9.77], p = 0.039). Right ventricular assist device was more common in the ECMO group (ECMO: 54.2% vs non‐ECMO: 11.7%, p < 0.001). Ischemic stroke was higher at one year in the ECMO group (ECMO: 25.0% vs non‐ECMO: 4.9%, p = 0.006). Among the study cohort, one‐year mortality was lower in HM3 than in HeartMate II (HMII) or HeartWare HVAD (10.5% vs 46.9% vs 31.6%, respectively; p < 0.001) recipients. Pump thrombosis at one year was lower in HM3 than in HMII or HVAD (1.8% vs 16.1% vs 16.2%, respectively; p = 0.026) recipients.Conclusions: Higher mortality was observed with ECMO as a bridge to LVAD, likely due to higher acuity illness, yet acceptable one‐year survival was seen compared with historical rates. The receipt of the HM3 was associated with improved survival compared with older generation devices.
- 1 January 2024
- Published by Wolters Kluwer Health in Circulation: Heart Failure
- Vol. 17 (1) , e011214
Direct VO 2 Measurement: Getting the Fick Right for Heart Transplant Eligibility
- 1 January 2024
- Published by Wolters Kluwer Health in Circulation: Heart Failure
- Vol. 17 (1) , e011214
Direct VO 2 Measurement: Getting the Fick Right for Heart Transplant Eligibility
- 27 September 2023
- Published by Wolters Kluwer Health in ASAIO Journal
- Vol. 69 (10) , 907-914
Effect of Anesthesia Induction on Cardiac Hemodynamics in Patients Undergoing Durable Left Ventricular Assist Device Implantation: The EACH-LVAD Study
Right ventricular (RV) dysfunction is common after left ventricular assist device (LVAD) implantation leading to clinical right heart failure (RHF) associated with worsened survival and quality of life. It is likely that intraoperative events such as anesthesia induction play a role in the development or unmasking of RV dysfunction in addition to known effects from hemodynamic changes that occur after LVAD implantation. The EACH-LVAD Study is a prospective, single-center, single-arm, observational cohort study of adult patients with advanced heart failure undergoing durable LVAD implantation with standard anesthesia induction. Intraoperative RV hemodynamics via central venous pressure, mean pulmonary artery pressure, pulmonary artery pulsatility index, and vasoactive-inotropic score (a simple weighted summation of standardized drug doses) and echocardiographic parameters (RV fractional area change, RV area in diastole, RV basal diameter, septum position, RV function, tricuspid regurgitation) were measured and compared at prespecified timepoints, including postinduction. Postoperative clinical RHF was determined based on published definitions. Forty-two patients receiving a first-time LVAD were included between September 2017 and March 2019. Propofol-based induction was used in 31 patients and etomidate-based induction in eight patients. A significant increase in central venous pressure (CVP; p < 0.001), mean pulmonary artery pressure (mPAP; p < 0.001), and vasoactive inotropic score (VIS; p < 0.001) with associated decrease in pulmonary artery pulsatility index (PAPi; p < 0.001) was observed. Right ventricular function worsened throughout. Right heart failure occurred in 70% of patients. Propofol-based induction was not associated with a higher risk of RHF (relative risk [RR], 1.01 [95% confidence interval {CI}, 0.64–1.61]). The EACH-LVAD study demonstrates an effect of anesthesia induction on worsened RV hemodynamics and echocardiographic changes which may have an effect on the development of RHF.
- 27 September 2023
- Published by Wolters Kluwer Health in ASAIO Journal
- Vol. 69 (10) , 907-914
Effect of Anesthesia Induction on Cardiac Hemodynamics in Patients Undergoing Durable Left Ventricular Assist Device Implantation: The EACH-LVAD Study
Right ventricular (RV) dysfunction is common after left ventricular assist device (LVAD) implantation leading to clinical right heart failure (RHF) associated with worsened survival and quality of life. It is likely that intraoperative events such as anesthesia induction play a role in the development or unmasking of RV dysfunction in addition to known effects from hemodynamic changes that occur after LVAD implantation. The EACH-LVAD Study is a prospective, single-center, single-arm, observational cohort study of adult patients with advanced heart failure undergoing durable LVAD implantation with standard anesthesia induction. Intraoperative RV hemodynamics via central venous pressure, mean pulmonary artery pressure, pulmonary artery pulsatility index, and vasoactive-inotropic score (a simple weighted summation of standardized drug doses) and echocardiographic parameters (RV fractional area change, RV area in diastole, RV basal diameter, septum position, RV function, tricuspid regurgitation) were measured and compared at prespecified timepoints, including postinduction. Postoperative clinical RHF was determined based on published definitions. Forty-two patients receiving a first-time LVAD were included between September 2017 and March 2019. Propofol-based induction was used in 31 patients and etomidate-based induction in eight patients. A significant increase in central venous pressure (CVP; p < 0.001), mean pulmonary artery pressure (mPAP; p < 0.001), and vasoactive inotropic score (VIS; p < 0.001) with associated decrease in pulmonary artery pulsatility index (PAPi; p < 0.001) was observed. Right ventricular function worsened throughout. Right heart failure occurred in 70% of patients. Propofol-based induction was not associated with a higher risk of RHF (relative risk [RR], 1.01 [95% confidence interval {CI}, 0.64–1.61]). The EACH-LVAD study demonstrates an effect of anesthesia induction on worsened RV hemodynamics and echocardiographic changes which may have an effect on the development of RHF.
- 2 June 2021
- Published by SAGE Publications in The International Journal of Artificial Organs
- Vol. 44 (10) , 787-790
SAVE score with lactate modification predicts in-hospital mortality in patients with ongoing cardiac arrest during VA-ECMO cannulation
The survival after veno-arterial extracorporeal membrane oxygenation score and its lactate modification predict in-hospital mortality in patients based on pre-extracorporeal membrane oxygenation variables. Cardiac arrest history is a significant variable in these scores; however, patients with ongoing cardiac arrest during cannulation were excluded from these models. The goal of this study is to validate the survival after veno-arterial extracorporeal membrane oxygenation score with a lactate modification among patients with ongoing cardiac arrest. In our study, the survival after veno-arterial extracorporeal membrane oxygenation score predicted mortality in all patients, but did so with higher discrimination among ongoing cardiac arrest patients with a lactate modification.
- 2 June 2021
- Published by SAGE Publications in The International Journal of Artificial Organs
- Vol. 44 (10) , 787-790
SAVE score with lactate modification predicts in-hospital mortality in patients with ongoing cardiac arrest during VA-ECMO cannulation
The survival after veno-arterial extracorporeal membrane oxygenation score and its lactate modification predict in-hospital mortality in patients based on pre-extracorporeal membrane oxygenation variables. Cardiac arrest history is a significant variable in these scores; however, patients with ongoing cardiac arrest during cannulation were excluded from these models. The goal of this study is to validate the survival after veno-arterial extracorporeal membrane oxygenation score with a lactate modification among patients with ongoing cardiac arrest. In our study, the survival after veno-arterial extracorporeal membrane oxygenation score predicted mortality in all patients, but did so with higher discrimination among ongoing cardiac arrest patients with a lactate modification.
- 7 February 2021
- Published by Wiley in The Journal of Clinical Pharmacology
- Vol. 61 (7) , 848-856
Fever Associated With Dexmedetomidine in Adult Acute Care Patients: A Systematic Review of the Literature
Dexmedetomidine‐associated fever has been reported in the literature and can lead to lengthy work‐ups and unnecessary antibiotic exposure. We conducted a systematic review to evaluate and describe the evidence of fever or hyperthermia caused by dexmedetomidine in adult patients. Data Sources include PubMed/MEDLINE, EMBASE, CINAHL, and Web of Sciences. English‐language studies of any design published from inception through April 2020 including conference abstracts were included. Target population was hospitalized adult patients. Quality of evidence was determined based on GRADE recommendations and risk of bias assessed using the Evidence Project risk of bias tool. Naranjo scores were assessed to determine likeliness of adverse event being caused by dexmedetomidine. All data was extracted independently and with the guidance of a medical librarian. 488 total citations were found on formal search with 329 left after removal of duplicates. Independent record screening was performed leaving 17 citations including 4 retrospective cohort studies, one case series, and 12 case reports. Quality of evidence ranged from very low to low for identified analyses. Evidence with patient level data (case reports and series) were combined to establish a cohort for descriptive results. The median Naranjo score was 4 (range 3–8) and dexmedetomidine doses ranged from 0.4‐2mcg/kg/h. Obesity and cardiac surgery appear to be significant risk factors. Dexmedetomidine‐associated fever appears uncommon but the true incidence is unknown. Clinicians should keep dexmedetomidine‐associated fever in their differential and stewardship programs should consider assessing for this adverse effect in their patient monitoring. This article is protected by copyright. All rights reserved
- 7 February 2021
- Published by Wiley in The Journal of Clinical Pharmacology
- Vol. 61 (7) , 848-856
Fever Associated With Dexmedetomidine in Adult Acute Care Patients: A Systematic Review of the Literature
Dexmedetomidine‐associated fever has been reported in the literature and can lead to lengthy work‐ups and unnecessary antibiotic exposure. We conducted a systematic review to evaluate and describe the evidence of fever or hyperthermia caused by dexmedetomidine in adult patients. Data Sources include PubMed/MEDLINE, EMBASE, CINAHL, and Web of Sciences. English‐language studies of any design published from inception through April 2020 including conference abstracts were included. Target population was hospitalized adult patients. Quality of evidence was determined based on GRADE recommendations and risk of bias assessed using the Evidence Project risk of bias tool. Naranjo scores were assessed to determine likeliness of adverse event being caused by dexmedetomidine. All data was extracted independently and with the guidance of a medical librarian. 488 total citations were found on formal search with 329 left after removal of duplicates. Independent record screening was performed leaving 17 citations including 4 retrospective cohort studies, one case series, and 12 case reports. Quality of evidence ranged from very low to low for identified analyses. Evidence with patient level data (case reports and series) were combined to establish a cohort for descriptive results. The median Naranjo score was 4 (range 3–8) and dexmedetomidine doses ranged from 0.4‐2mcg/kg/h. Obesity and cardiac surgery appear to be significant risk factors. Dexmedetomidine‐associated fever appears uncommon but the true incidence is unknown. Clinicians should keep dexmedetomidine‐associated fever in their differential and stewardship programs should consider assessing for this adverse effect in their patient monitoring. This article is protected by copyright. All rights reserved